Please assess the completion status of the following clinical trial:

Trial Title: Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index within the range 18.5-35.0 kilograms/metre2 (kg/m2).~* Females of non-child bearing potential.~* Documented history of bronchial asthma, first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta -agonist therapy by inhalation~* Pre-bronchodilator FEV1 \>70% of predicted at screening~* Subjects who are current non-smokers~* Methacholine challenge PC20 \< 8 mg/mL at screening~* Screening allergen challenge demonstrates that the subject experiences an early asthmatic response~Exclusion Criteria:~* Current or chronic history of liver disease, or known hepatic or biliary abnormalities~* Subject is hypertensive at screening~* Respiratory tract infection and/or exacerbation of asthma within 4 weeks prior to the first dose of study medication.~* History of life-threatening asthma~* Symptomatic with hay fever at screening or predicted to have symptomatic hayfever~* Unable to abstain from short acting beta agonists~* Unable to abstain from antihistamines~* Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDs), anti-depressant drugs, anti-asthma anti-rhinitis or hay fever medication~* The subject has participated in a study with a new molecular entity during the previous 3 months or has participated in 4 or more clinical studies in the previous 12 months~* undergoing allergen desensitisation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Inhaler
- inhaled corticosteroid(ICS)/long acting bronchodilator (LABA) (Type: ACTIVE_COMPARATOR): ICS/LABA inhaler
- ICS (Type: ACTIVE_COMPARATOR): ICS inhaler

Based on this trial design, predict the completion outcome and termination type (if applicable).